Vaxcyte, Inc. PCVX Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vaxcyte, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vaxcyte, Inc.'s financing cash flow?
- Vaxcyte, Inc. (PCVX) reported financing cash flow of $601.58M in Q1 2026.
- How has Vaxcyte, Inc.'s financing cash flow changed year-over-year?
- Vaxcyte, Inc.'s financing cash flow increased by 79159.9% year-over-year, from $759K to $601.58M.
- What is the long-term trend for Vaxcyte, Inc.'s financing cash flow?
- Over 4 years (2021 to 2025), Vaxcyte, Inc.'s financing cash flow has grown at a -42.0% compound annual growth rate (CAGR), from $17.8M to $2.01M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.